Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FB2001 inhalation in healthy Chinese adults
NCT05583812Phase 1Completed
- Sponsor
- Frontier Biotechnologies Inc.
- Start
- Oct 2022
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of Compound 7b in coronavirus disease 2019 (COVID-19) (4 arms), sponsored by Frontier Biotechnologies Inc. Primary endpoints: Safety and tolerability after single and multiple doses at Day 14, Area under the concentration-time curve from time zero to the last measurable concentration at Day 14 and 1 more. Started Oct 2022; status: completed.
02
Drugs
Compound 7b
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05583812.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05583812.